Skip to content
OpenCapital
Get started

Akebia Therapeutics AKBA Q4 2024 Annual earnings

Reported March 13, 2025 · Before market open

Revenue$46.5MBeat by $9.1M
EPS-$0.10Miss by $0.05
Revenue estimate$37.4M
EPS estimate-$0.05

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$48.9M
EPS estimate-$0.03

Versus estimates

Revenue

Q1 2026$53.5MBeat by $1.9MQ4 2025$57.6MBeat by $11.5MQ3 2025$58.8MBeat by $10.4MQ2 2025$62.5MBeat by $14.6MQ1 2025$57.3MBeat by $6.5M
Q4 2024$46.5MBeat by $9.1M

Diluted EPS

Q1 2026-$0.03Miss by $0.02Q4 2025-$0.05Miss by $0.02Q3 2025$0.00Beat by $0.06Q2 2025$0.00Beat by $0.02Q1 2025$0.03Beat by $0.06
Q4 2024-$0.10Miss by $0.05

Ask the moment Akebia Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Akebia Therapeutics report Q4 2024 earnings?
Akebia Therapeutics (AKBA) reported Q4 2024 earnings on March 13, 2025 before market open.
What were Akebia Therapeutics's Q4 2024 revenue and EPS?
Akebia Therapeutics reported revenue of $46.5M and eps of $-0.10 for Q4 2024.
Did Akebia Therapeutics beat estimates in Q4 2024?
Revenue beat the consensus estimate of $37.4M by $9.1M. EPS missed the consensus estimate of $-0.05 by $0.05.
Where can I find Akebia Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-012470) directly on SEC EDGAR. The filing index links above go to sec.gov.